Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889119 | 0.95 | CYP2C19 (0.34) | ALDH1A1HPGDAPOBEC3GCYP2C19 | |
| SCHEMBL5889273 | 0.93 | NR1H2 (0.33) | ALDH1A1HPGDAPOBEC3GCYP2C19 | |
| SCHEMBL5889275 | 0.93 | NR1H2 (0.33) | ALDH1A1HPGDAPOBEC3GCYP2C19 | |
| SCHEMBL5889253 | 0.89 | CYP2C19 (0.37) | CYP2C19ESR1ESR2 | |
| SCHEMBL19622284 | 0.77 | CES2 (0.32) | ALDH1A1HPGD | |
| SCHEMBL6290380 | 0.73 | — | — | |
| SCHEMBL23700979 | 0.68 | — | — | |
| SCHEMBL2622738 | 0.68 | NR1H2 (0.54) | ALDH1A1HPGDESR1ESR2 | |
| SCHEMBL5011624 | 0.68 | — | — | |
| SCHEMBL10623191 | 0.68 | ALDH1A1 (0.34) | ALDH1A1HPGDAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194827-A1 | 5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS, INCORPORATED | 2006-08-31 | — | — | US | disclosed |
| US-7071205-B2 | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1551845-A1 | 5-CYCLOALKENYL 5 i H /i -CHROMENO 3,4-F QUINOLINE DERIV ATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS, INC. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040152718-A1 | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2004-08-05 | — | — | US | disclosed |
| WO-2004033460-A1 | 5-CYCLOALKENYL 5H-CHROMENO[3,4-F]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194827-A1 | 5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds | PGR, GPER1, FSHR | ALDH1A1 3556/4885HPGD 474/4885APOBEC3G 4428/4885 |
| US-20040152718-A1 | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds | PGR, GPER1, PGRMC2 | ALDH1A1 2500/4885HPGD 551/4885APOBEC3G 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.